John E. Milad profile page

As CEO of ERS Genomics, John has over 25 years’ experience as an executive, board member, venture capital investor, and investment banker focused on the life sciences and MedTech sectors. As CEO of Quanta Dialysis Technologies for nearly a decade, John led the development and commercial launch of an award-winning portable hemodialysis system designed to transform the delivery of kidney care to patients. He drove market entry into the UK and US, while raising a record-breaking $245 million private funding round and clinching the prestigious MacRobert Award for engineering excellence. Prior to this, he served as CFO of Nitec Pharma, securing a pivotal funding round and key partnerships that transitioned the company from development to commercial stage. John is also an experienced venture investor, with previous roles as Partner and co-Head of Healthcare Ventures at Downing LLP and Investment Director at NBGI Ventures. Before that, he worked at Atlas Venture and Kirkland Investors. Successful exited investments include Symetis, ACT/Epix, BoneSupport, and WebMD. John is a graduate of the University of Chicago and previously served on the i4i selection panel for translational research at the National Institute for Health and Care Research (NIHR). He currently serves as an independent Board member at Otivio AS and is a mentor at the Enterprise Hub of the Royal Academy of Engineering. John was named in the Sunday Times Maserati List as one of the UK’s “Top 100 Game Changing Innovators and Entrepreneurs.”